At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 63 enrolled
Drug / intervention
IO102-IO103 in combination with pembrolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Multi-Arm (Basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination With Pembrolizumab, as First-Line Treatment for Patients With Metastatic NSCLC, SCCHN, or Metastatic mUBC
In Brief
A Phase 2 clinical trial evaluating IO102-IO103 in combination with pembrolizumab for Lung Cancer Non Small Cell and 2 related conditions. Completed, enrolled 63 participants across 21 sites in 3 countries.
Detailed Summary
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head or Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder
CountriesSpain, United Kingdom, United States
CollaboratorsTheradex, Almac, NeoGenomics, Merck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedOct 2021
Enrollment StartApr 2022
Primary CompletionNov 2025
Study CompletionFeb 2026
TodayJul 2026
First PostedOct 14, 2021
Enrollment StartApr 11, 2022
Primary CompletionNov 30, 2025
Study CompletionFeb 8, 2026
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 4.7 years ago
Interventions
IO102-IO103 in combination with pembrolizumabdrug
The experimental drug IO102-IO103 is for SC injection and consist of IDO and PD-L1 peptides